Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.
about
Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicA review of antibiotic use in food animals: perspective, policy, and potentialRetargeting R-type pyocins to generate novel bactericidal protein complexesIn vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection modelColistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patientsCan we prevent antimicrobial resistance by using antimicrobials better?Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combinationAcinetobacter baumannii: evolution of a global pathogenAntimicrobial polymeric materials with quaternary ammonium and phosphonium saltsSelective labelling and eradication of antibiotic-tolerant bacterial populations in Pseudomonas aeruginosa biofilms.Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial AgentsStructures of Helicobacter pylori Shikimate Kinase Reveal a Selective Inhibitor-Induced-Fit MechanismConstrained peptides with target-adapted cross-links as inhibitors of a pathogenic protein-protein interactionAntimicrobial Stewardship: How the Microbiology Laboratory Can Right the ShipAntimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.A comparative study on the cost of new antibiotics and drugs of other therapeutic categoriesTargeting the replication initiator of the second Vibrio chromosome: towards generation of vibrionaceae-specific antimicrobial agentsNovel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathwaysDetection of quorum sensing signal molecules and identification of an autoinducer synthase gene among biofilm forming clinical isolates of Acinetobacter sppEndemic Acinetobacter baumannii in a New York hospitalIsolation and biological evaluation of N-(4-aminocyclooctyl)-3, 5-dinitrobenzamide, a new semisynthetic derivative from the Mangrove-associated actinomycete Pseudonocardia endophytica VUK-10Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaThe role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae.Newer antibacterial drugs for a new century.Inhibitors of RecA activity discovered by high-throughput screening: cell-permeable small molecules attenuate the SOS response in Escherichia coli.Probing the penetration of antimicrobial polymyxin lipopeptides into gram-negative bacteriaImproving antimicrobial prescribing in Irish primary care through electronic data collection and surveillance: a feasibility study.Identification and characterization of an Acinetobacter baumannii biofilm-associated protein.Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides.Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitorsA role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in Aspergillus fumigatus.New disturbing trend in antimicrobial resistance of gram-negative pathogensComparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity.Evaluation of existence and transmission of extended spectrum beta lactamase producing bacteria from post-delivery women to neonates at Bugando Medical Center, Mwanza-TanzaniaUniversal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trialNovel Inhibitors of E. coli RecA ATPase Activity.MarA, SoxS and Rob of Escherichia coli - Global regulators of multidrug resistance, virulence and stress response.Antibiotic sensitivity pattern of gram negative bacilli isolated from the lower respiratory tract of ventilated patients in the Intensive care unit.Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.
P2860
Q24614464-69BD331D-DA74-4425-8EC2-15FE436748C1Q24630387-12B01749-3CEC-4DD6-9577-F98599828B34Q24647143-70E54C1C-32E9-4DAC-AF3E-669701651AFDQ24654780-EA497E3D-1FB5-4DF8-82F1-7499B0151BA0Q24673399-A08647B1-667B-4F18-A516-2EAC6E4E61F5Q26829707-DC40BBA9-3AE6-4761-8698-18B2B92256A8Q26998883-E7B23AE5-7A37-4FF5-8E04-FD8C8B9D3D5FQ27008568-908937D2-D367-477C-9C25-C820077145F6Q27021973-BF2E8669-1B63-4046-A01E-87AB9D4CEA3FQ27331155-22D5A6FC-92E6-4B3A-853D-849A8567FF12Q27676314-1099518B-5997-4539-BB97-55997EE85193Q27678149-5C7D0659-EF0F-4C22-B8FF-4415265FD1F0Q27689051-1F3DF067-3137-422B-9C23-99E3360DE4ACQ28068503-2868771F-23E8-4884-AE41-6AB7C6FA0542Q28393128-F6A52EC7-8430-4E8E-A5C6-13D634469C08Q28469093-8DE0743B-FB3B-455A-8E84-F970C0A35AA9Q28471879-584B053A-43ED-4A34-88B1-A14BCD450F1DQ28473763-947A8E8B-FBF8-400A-9CEF-FF4B88FE547EQ28481357-54022E37-32BA-4DFE-971A-C066460ACE7BQ28741550-97C67654-28AE-455F-AB5A-1D599F7A7882Q28828673-8ABDFF40-BB76-400A-9BAB-1F13B32EA022Q29616084-F751D99D-0276-427D-8B41-61CED0CD3721Q30300020-0BF4B56E-7BDA-491A-B614-4488A647231AQ30433333-939D7B84-B07C-4FAC-88E8-BADF534DAEF2Q30479751-34A48C64-DA74-4DEB-891E-1DE3167A5EA0Q30576597-4AC63633-CEC3-473E-897B-45754A83EDB2Q30978227-74F44B17-65D1-4996-9DA8-F4B3E9F9EF4DQ33306299-A445DED1-13EB-400E-864B-9C72CC53D79AQ33332126-F7D22000-327B-4116-AF96-4EEECE5F71C1Q33339829-CEFBD4CC-300A-4A3A-992B-E9455B1AFA32Q33398514-ED769F20-E1A2-4C6E-BD51-0FB158F2274EQ33422956-B7E4358F-73D2-43C0-9F71-3A6797068FB5Q33508985-D67BD94E-34D2-4C10-8007-49DB8DCBB6A5Q33525706-A06E4CF7-F55D-4DFA-AF04-B13E0E756E73Q33584402-9CF09967-1E5D-4522-BEF9-F807BCB77218Q33632050-41343BF4-9906-411A-9918-A52A0CC024C3Q33637395-4C2FC93B-2C64-4083-B192-B592274C1595Q33652762-2918A2C6-EB95-4E73-9DEE-C8E9CFBE67D2Q33659555-EBDF3DFA-5011-4F15-A63E-9B7A27416176Q33676366-0185B895-CB02-43F3-B6CD-F8562EC8ABE6
P2860
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Bad bugs need drugs: an update ...... s Diseases Society of America.
@ast
Bad bugs need drugs: an update ...... s Diseases Society of America.
@en
type
label
Bad bugs need drugs: an update ...... s Diseases Society of America.
@ast
Bad bugs need drugs: an update ...... s Diseases Society of America.
@en
prefLabel
Bad bugs need drugs: an update ...... s Diseases Society of America.
@ast
Bad bugs need drugs: an update ...... s Diseases Society of America.
@en
P2093
P2860
P356
P1476
Bad bugs need drugs: an update ...... s Diseases Society of America.
@en
P2093
Antimicrobial Availability Task Force of the Infectious Diseases Society of America
David Gilbert
George H Talbot
John Bradley
John E Edwards
John G Bartlett
Michael Scheld
P2860
P304
P356
10.1086/499819
P407
P577
2005-01-25T00:00:00Z